Guggenheim Boosts InflaRx (NASDAQ:IFRX) Price Target to $22.00

InflaRx (NASDAQ:IFRX) had its price target lifted by Guggenheim from $10.00 to $22.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

A number of other equities analysts have also issued reports on IFRX. HC Wainwright started coverage on shares of InflaRx in a research report on Tuesday, September 2nd. They set a “buy” rating and a $6.00 price target for the company. Wall Street Zen cut shares of InflaRx from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $8.60.

InflaRx Stock Up 2.5%

IFRX opened at $1.23 on Monday. The company has a market cap of $82.57 million, a P/E ratio of -1.54 and a beta of 1.38. The firm’s 50-day moving average price is $1.38 and its 200-day moving average price is $1.18. InflaRx has a 52-week low of $0.71 and a 52-week high of $2.82.

InflaRx (NASDAQ:IFRX) last released its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.02 million. On average, research analysts anticipate that InflaRx will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On InflaRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new stake in InflaRx in the 1st quarter valued at $38,000. DAFNA Capital Management LLC acquired a new position in shares of InflaRx during the 1st quarter valued at about $459,000. Cubist Systematic Strategies LLC boosted its position in shares of InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after acquiring an additional 7,616 shares during the last quarter. 683 Capital Management LLC grew its holdings in shares of InflaRx by 26.8% in the first quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after purchasing an additional 555,000 shares during the period. Finally, Woodline Partners LP acquired a new stake in InflaRx during the first quarter worth about $766,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.